Meeting
2023 ASCO Annual Meeting
A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio.
Authors
Paul James Mulholland
University College Hospital-London, London, United Kingdom
Paul James Mulholland , Nicholas Fraser Brown , Catherine McBain , Lucy Brazil , Sharon Peoples , Sarah Jefferies , Fiona Harris , Puneet Plaha , Anup Vinayan , Claire Brooks , Samia Hussain , Susan J. Dutton , Stasya Ng , Stephanie Levy , Timothy Coutts
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
ISRCTN84434175
Citation
J Clin Oncol 41, 2023 (suppl 17; abstr LBA2023)
DOI
10.1200/JCO.2023.41.17_suppl.LBA2023
Abstract #
LBA2023
Poster Bd #
380
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen
Poster
2014 ASCO Annual Meeting
Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II clinical trial.
First Author: Mustafa Khasraw
Poster
2013 ASCO Annual Meeting
The Stupp regimen preceded by early post-surgery temozolomide versus the Stupp regimen alone in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM).
First Author: LF Zhou
Poster
2011 ASCO Annual Meeting
CeCil: A randomized, noncomparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma.
First Author: V. Verschaeve